4 Top Pharma Stocks That Should Outperform Out To 2016
ThinkstockWith a very nervous market, and the end of summer doldrums upon us, it may be time to look for ideas that will make sense when the market heats back up in the fall.…
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 252Aclaris Gets Ready For Its Initial Public Offering
ThinkstockAclaris Therapeutics, Inc. filed an S-1 form with the Securities and Exchange Commission (SEC) for its initial public offering (IPO). There were no terms given for the filing but the offering is valued up…
Agilent Beats on Profits, but Guidance Does Not Match Analyst Expectations
ThinkstockAgilent Technologies Inc. (NYSE: A) reported third fiscal quarter 2015 earnings after markets closed Monday. For the quarter, healthcare company posted adjusted diluted earnings per share (EPS) of $0.44 on revenues of $1.01 billion.…
What the Cord Blood Registry Buyout Really Adds to AMAG
ThinkstockAMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) had already seen shares rise handily prior to the summer selloff. While this deal is a known event, it looks as though AMAG may have just scored after it…
SynCardia Prepares For IPO
Thinkstock Medical device maker SynCardia Systems, Inc. filed an S-1 form with the Securities and Exchange Commission (SEC) for its initial public offering (IPO). There were no terms given in the filing but the offering…
Kite Pharma Updates Study, Dispells Rumors
Kite Pharma gave an update from its ongoing Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive non-Hodgkin's lymphoma.
Is AVEO the Next Aquinox for Traders?
Aveo Pharmaceuticals made waves in early trading indications Monday on news of a licensing agreement with Novartis.
Credit Suisse Sees Big Biopharma Upside in Top Contract Research Outfits
Credit Suisse assumed coverage with handy upside in the CRO leaders, and on average the firm is calling for upside of about 15%.
Why Onconova Is on the Move
Onconova Therapeutics has announced the submission of an investigational new drug application to the FDA.
Aquinox Pharma Continues to Impress Investors
Aquinox Pharmaceuticals has made an absolutely ridiculous run in the past week alone, proving that it is a day trader’s dream.
JPMorgan Has Favorite Biotech Stocks to Buy for Rest of 2015
In a new research report, JPMorgan highlights its favorite biotech stocks to buy after the second-quarter earnings print.
Why the FDA Extended Review Date on Key Melanoma Drug Opdivo
Bristol-Myers Squibb announced that the FDA has now extended the action date for the supplemental biologics license application for Opdivo in the war against advanced melanoma.
Big First-Day Pop for Global Blood Therapeutics IPO
A biopharmaceutical company working on developing and commercializing treatments for serious blood-based disorders priced its initial public offering (IPO) above the expected range Tuesday.
Can Eleven Bio Get Back to Even With This Study?
Eleven Biotherapeutics was at the top of the list for gainers in the market Wednesday. This move comes on an update from the company’s most advanced study.
Short Sellers Back Off Big Pharma
The short interest data have been released for the July 31 settlement date, and for most of the selected pharmaceutical stocks, short interest decreased.